Search for: "Mylan, Inc."
Results 101 - 120
of 673
Sort by Relevance
|
Sort by Date
19 Aug 2019, 11:39 am
Mylan Laboratories Ltd., 757 Fed. [read post]
24 Jun 2019, 10:00 pm
Mylan Pharmaceuticals, Inc., 896 F.3d 1322 (Fed. [read post]
18 Jun 2019, 11:31 am
Mylan Pharmaceuticals Inc., 896 F.3d 1322 (Fed. [read post]
16 Jun 2019, 9:30 pm
Mylan Pharmaceuticals Inc.), held that State sovereign immunity does not preclude institution of inter partes review proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. [read post]
14 Jun 2019, 12:24 pm
Mylan Pharmaceuticals Inc., 896 F.3d... [read post]
14 Jun 2019, 12:24 pm
Mylan Pharmaceuticals Inc., 896 F.3d 1322 (Fed. [read post]
14 May 2019, 11:24 am
Mylan Labs., Inc., 464 F.3d 1286,1289 (Fed. [read post]
14 May 2019, 11:12 am
See Housey Pharm., Inc. v. [read post]
8 May 2019, 7:14 am
” It’s not enough to put an unapproved drug on the market with a FDA-ish package insert, according to Mylan Labs., Inc. v. [read post]
17 Mar 2019, 3:11 am
PatentsThe Kluwer Patent Blog reports on the results of the EPO's online user consultation concerning a procedural option for postponing examination of a European patent application and on the decision of the Danish Maritime and Commercial Court to grant an injunction against Mylan AB's sale of the product Tadalafil »Mylan« containing 5 mg Tadalafil in Denmark. [read post]
13 Mar 2019, 9:10 am
Mylan Pharmaceuticals, Inc., et al., No. 18-899 (May tribal sovereign immunity may be asserted to bar IPR review of patents owned by the tribe?) [read post]
11 Mar 2019, 7:08 pm
The Momenta Appeal At the time of its 2015 petition for inter partes review, Momenta was working with Mylan to develop a biosimilar counterpart to Orencia®, the branded biologic drug whose active ingredient was covered by the BMS patent. [read post]
4 Mar 2019, 1:14 pm
Mylan, Inc., 853 F.3d 1296, 1302 n.1(Fed. [read post]
28 Feb 2019, 8:47 pm
Mylan Laboratories... [read post]
21 Feb 2019, 9:29 pm
Mylan Pharmaceuticals Inc., No. 2018-2097 ("Valeant II"), Salix moves to disqualify in Salix Pharmaceuticals, Inc. v. [read post]
21 Feb 2019, 12:11 pm
Mylan Pharma., Inc., available here. [read post]
21 Feb 2019, 8:45 am
Mylan Pharmaceuticals Inc., No. 2018-2097 (“Valeant II”), Salix moves todisqualify in Salix Pharmaceuticals, Inc. v. [read post]
14 Feb 2019, 9:50 pm
RE38,551 challenged in inter partes review were not unpatentable for obviousness, in Mylan Pharmaceuticals Inc. v. [read post]
14 Feb 2019, 7:05 am
Mylan Pharmaceuticals Inc. 18-899 Issue: Whether inter partes review before the Patent Trial and Appeal Board is the type of proceeding in which tribal sovereign immunity may be asserted. [read post]
7 Feb 2019, 5:36 pm
In Momenta Pharmaceuticals, Inc. v. [read post]
